Harnessing AI and Real-World Data to Transform Oncology Research

As artificial intelligence becomes increasingly embedded in healthcare research, the ability to generate reliable, transparent, and regulatory-grade eviden...

May 01, 2026 | Friday | Interview
Advancing Equity in Precision Oncology: Insights from Real-World Genomic Testing Trends in Metastatic Prostate Cancer

As precision medicine continues to reshape cancer care, ensuring equitable access to genomic testing remains a critical priority. New research presented at...

June 01, 2026 | Monday | Interaction
Anticipating ASCO 2026: A Preview of Breakthrough Advances in Precision Oncology and Next-Generation Cancer Therapies

    What's Coming to ASCO 2026: Sneak Peek at Transformative Cancer Research The American Society of Clinical Oncology (ASCO) 2026 Annual Meet...

May 25, 2026 | Monday | Analysis
Inside the Future of Biopharma Manufacturing: AES on Cleanroom Innovation, Contamination Control, and Operational Resilience

From advanced biologics and cell therapies to increasingly stringent regulatory expectations, today’s pharmaceutical manufacturing environments dem...

May 18, 2026 | Monday | Interaction
FUJIFILM Corporation Unveils Novel Cyclic Peptide Screening Technology for Challenging Membrane Protein Drug Targets

FUJIFILM Corporation announced that it has developed an innovative screening methodology for cyclic peptides exhibiting high affinity toward membrane pro...

May 11, 2026 | Monday | News
Immatics’ PRAME-Directed TCR T-Cell Therapy Drives Deep Remission in Pediatric Solid Tumor Case

Individual experimental treatment attempt at Hopp Children’s Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a TC...

April 21, 2026 | Tuesday | News
Sanofi’s Nuvaxovid Shows Superior Tolerability vs mNEXSPIKE in Head-to-Head Study

Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase...

April 21, 2026 | Tuesday | Reports
KIMMTRAK Doubles Five-Year Survival in First-Line Metastatic Uveal Melanoma

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit observed ac...

April 21, 2026 | Tuesday | News
PRAME-Targeted TCR T-Cell Therapy Drives Deep Remission in Pediatric Cancer Case

Individual experimental treatment attempt at Hopp Children’s Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a TC...

April 20, 2026 | Monday | News
Evaxion’s EVX-01 Shows Record 86% Immune Response Rate in Phase 2 Personalized Cancer Vaccine Study

New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response...

April 20, 2026 | Monday | News
Cepheid And Oxford Nanopore Expand Collaboration To Advance Rapid Pathogen Genomic Workflows

Phase two collaboration aims to expand access to streamlined genomic workflows for infectious disease research Cepheid, a Danaher company and a leader i...

April 16, 2026 | Thursday | News
Eli Lilly and Company Showcases Dual-Therapy Breakthrough in Psoriatic Arthritis and Obesity at AAD 2026

Eli Lilly and Company announced detailed results from the TOGETHER-PsA open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekiz...

March 30, 2026 | Monday | News
ATA-200 Gene Therapy Shows Early Clinical Promise for LGMD-R5 in First Patients

Atamyo Therapeutics, a biotechnology company specializing in the development of next-generation gene therapies for limb-girdle muscular dystrophy (LGMD),...

March 10, 2026 | Tuesday | News
Celltrion, Inc. Highlights Subcutaneous Infliximab’s Ability to Restore and Sustain Disease Control in IBD Patients Through Week 102

Celltrion, Inc. announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), showing that subcutaneous (SC) in...

February 17, 2026 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close